LJPC

[nullzero]

Shorted LJPC today @ 6.95  . LJPC has a bad history of dilution to fund its operations. I dont think LJPC will be above 6 for long  .

[setravis]

Phase III drug awaits approval.......
has a drug in phase III for FDA approval which, if approved, would be the only drug available for renal lupus, a disease that afflicts up to 1.5 million people in this country alone.

This play is intriguing because the insiders are snapping up shares with their own money. This tells me that they are confident about their drug getting FDA approval.

Furthermore, a recent secondary stock offering was issued, and it was over-subscribed by the underwriters, which indicates that demand is strong for this stock.

Counting directors and venture capital funds, a total of $31 million of stock has been purchased just in this month alone (April). Most of the stock was purchased at around $6.00, and within days, the stock reached $8.48 (on 4/10), but the secondary diluted the stock down to $7.10 or so...

The P&F chart points to a price objective of nearly $20!!! AG Edwards just issued a "Buy" rating a few days ago with a price objective of $11....it seems like pretty good value here, although any bad news from the FDA could seriously hammer the price down.

MACD remains in positive territory, despite the recent dilution, and the price has remained stable enough in recent days.

Still, I think everything is setting up for a "Home Run" on LJPC. JMHO of course.......

52wk Range: 2.77 - 8.68
Volume: 873,725
Avg Vol (3m): 704,024

Technicals
Percentage Gainer

Last Price Quote is:
3.07%above 13-day MA
21.15%above 50-day MA
RS Rating: 98 

Fundamentals
Key Data:
Market Cap (M): $216.55 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 05/10/2007
Last Analyst Rating: Buy

[boatguy]

Large insider buy- taking off

[setravis]

Updated chart scene...

[setravis]

Updated chart scene

LJPC - Volume Alert...

La Jolla Pharmaceutical Company, a biopharmaceutical company, engages in the discovery and development of orally-active small molecules for the treatment of autoimmune diseases, and acute and chronic inflammatory disorders.

52wk Range: 0.04 - 3.20
Volume: 45,099,073
Avg Vol (3m): 5,907,700

Technicals
Close Above the 13-day MA
Most Actives
Percentage Gainer

Last Price Quote is:
155.29%above 13-day MA
45.39%above 50-day MA
RS Rating: 2 

Fundamentals
Earnings Expected on May 7

Key Data:
Market Cap (M): $7.61 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 08/10/2009
Last Analyst Rating: Hold

[setravis]

updated chart look...
Let's see what takes place with this Symmetrical Triangle.